Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Pazdur Jumps Over To New 'Moonshot' Role

This article was originally published in The Pink Sheet Daily

Executive Summary

Creation of agency's new Oncology Center of Excellence means the Office of Hematology and Oncology Products, often seen as FDA's model product review shop, needs new leadership – at least temporarily.


Related Content

US FDA May Create Immunology, Neuroscience Centers Of Excellence
US FDA's Oncology Division Wants To Know About Your Pipeline, Not Just Your NDAs
US FDA Drug Office Reform: 'Everything' Is On The Table
FDA's Oncology Center Of Excellence On Equal Terms With CDER In New Org Chart
Gottlieb's FDA: Specialized Groups Could Create Review Consistency, Speed
Pediatric Drug Development A Priority For US FDA’s New Oncology Center Of Excellence
Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?
FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence
FDA's Califf Seeks His First Big Hire: Chief Scientist
FDA Chief Scientist Post A Chance For Califf To Make Mark

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts